Τετάρτη 17 Μαρτίου 2021

Human menstrual blood-derived stem cells as immunoregulatory therapy in COVID-19: A case report and review of the literature

paythelady.612 shared this article with you from Inoreader

World J Clin Cases. 2021 Mar 6;9(7):1705-1713. doi: 10.12998/wjcc.v9.i7.1705.

ABSTRACT

BACKGROUND: The coronavirus disease 2019 (COVID-19) caused by novel coronavirus 2019 in December 2019 has spread all around the globe and has caused a pandemic. There is still no current effective guidance on the clinical management of COVID-19. Mesenchymal stem cell therapy has been shown to be one of the therapeutic approaches to alleviate pneumonia and symptoms through their immunomo-dulatory effect in COVID-19 patients.

CASE SUMMARY: We describe the first confirmed case of COVID-19 in Hangzhou to explore the role of human menstrual blood-derived stem cells (MenSCs) in the treatment of COVID-19. Moreover, we review the immunomodulation effect including non-specific and specific immune functions of MenSCs for the therapy of COVID-19.

CONCLUSION: MenSCs can be helpful to find a promising therapeutic approach for COVID-19.

PMID:33728315 | PMC:PMC7942055 | DOI:10.12998/wjcc.v9.i7.1705

View on the web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου